Targeting of cancer-associated fibroblasts with drug-loaded polymeric nanoparticles to improve im-mune therapy for primary and secondary liver tumors (B17*)

纳米颗粒被CAF靶向配体修饰，负载CAF调节药物(例如抗转化生长因子β1siRNA，AT1R拮抗剂)，并在体外进行测试(在I.A.肿瘤有机化合物)，以选择有希望的候选者进行体内治疗实验。在用多模式成像方法评价载药纳米粒的生物分布和肿瘤组织蓄积后，在相关的小鼠肝肿瘤模型上研究了不同载药纳米粒的抗肿瘤作用。RNA和蛋白质组学被应用于深入了解治疗机制。

Nanoparticles are decorated with CAF-targeting ligands, loaded with CAF-modulating drugs (e.g. anti-TGFβ1 siRNA, AT1R-antagonists) and tested in vitro (in i.a. tumor organoids) to select promising candidates for therapeutic in vivo experiments. After biodistribution and tumor tissue accumulation of the drug-loaded na-noparticles have been assessed by multimodal imaging methods, therapeutic antitumor effects of the vali-dated drug-loaded nanoparticles are studied in relevant murine liver tumor models, whereby i.a. RNA- and proteomics are applied to gain insight into therapeutic mechanisms.